Consensus Roivant Sciences Ltd.

Equities

ROIV

BMG762791017

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
11.03 ^USD	+1.38%		+5.45%	-1.78%

Apr. 05	Arbutus Biopharma Obtains Favorable Court Order in Moderna Patent Lawsuit	MT
Apr. 04	Moderna Suffers Setback in Lawsuit by Arbutus	MT

Evolution of the average Target Price on Roivant Sciences Ltd.

Price target over the last 5 years

History of analyst recommendation changes

c869259f06c561adf68eeb5364f.mnqJCIpThG8yOeP0xuquMMxNpOMIjbtM-M9ek47juNc.2znRXd4y6jVqf7WZopz3BIQo8YdBvMt_l7sE6d-n9YfDCr9EwGDPGENLkA~39cc90a55f4b78fd727f55304269be6d

Analyst Recommendations on Roivant Sciences Ltd.

Deutsche Bank Raises Roivant Sciences' Price Target to $15 From $14, Maintains Buy Rating	Apr. 03	MT
Goldman Sachs Raises Roivant Sciences' Price Target to $18 From $16, Maintains Buy Rating	Apr. 03	MT
HC Wainwright Raises Roivant Sciences Price Target to $18 From $17, Maintains Buy Rating	Apr. 03	MT
Wolfe Research Initiates Roivant Sciences With Outperform Rating, $17 Price Target	Feb. 15	MT
Deutsche Bank Initiates Coverage on Roivant Sciences With Buy Rating, $14 Price Target	Dec. 12	MT
Goldman Sachs Raises Roivant Sciences Price Target to $16 From $14, Maintains Buy Rating	23-09-27	MT
Wall St slides as rate concerns keep Treasury yields near 16-year peak	23-09-26	RE
Wall St poised for weak open as rate worries keep Treasury yields elevated	23-09-26	RE
HC Wainwright Adjusts Roivant Sciences Price Target to $18 From $15, Maintains Buy Rating	23-06-29	MT
Truist Securities Adjusts Price Target on Roivant Sciences to $23 From $19, Maintains Buy Rating	23-06-23	MT
BofA Securities Starts Roivant Sciences at Neutral With $10.50 Price Target	23-06-08	MT
JPMorgan Adjusts Roivant Sciences Price Target to $14 From $12, Maintains Overweight Rating	23-05-18	MT
HC Wainwright Adjusts Price Target on Roivant Sciences to $15 From $14, Maintains Buy Rating	23-05-17	MT
JPMorgan Adjusts Price Target on Roivant Sciences to $11 From $10, Maintains Overweight Rating	23-02-13	MT
Goldman Sachs Adjusts Price Target on Roivant Sciences to $11 From $10, Maintains Buy Rating	23-01-19	MT
Citigroup Adjusts Price Target on Roivant Sciences to $14 From $11, Maintains Buy Rating	23-01-05	MT
SVB Securities Adjusts Price Target on Roivant Sciences to $10 From $8, Maintains Outperform Rating	22-12-19	MT
Citigroup Adjusts Price Target on Roivant Sciences to $11 From $10, Maintains Buy Rating	22-11-15	MT
Citigroup Raises Roivant Sciences' Price Target to $10 From $9, Maintains Buy Rating	22-08-16	MT
SVB Securities Adjusts Roivant Sciences' Price Target to $7 from $6, Keeps Outperform Rating	22-06-29	MT
Goldman Sachs Adjusts Roivant Sciences Price Target to $12 From $15, Maintains Buy Rating	22-05-24	MT
Goldman Sachs Lowers Roivant Sciences; Price Target to $12 From $15, Maintains Buy Rating	22-05-24	MT
SVB Securities Initiates Roivant Sciences at Outperform With $6 Price Target	22-05-23	MT
Cantor Fitzgerald Initiates Roivant Sciences at Overweight with $15 Price Target	22-04-29	MT
Goldman Sachs Starts Roivant Sciences at Buy With $15 Price Target	21-12-15	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

11.03 USD

Average target price

16.08 USD

Spread / Average Target

+45.78%

High Price Target

20 USD

Spread / Highest target

+81.32%

Low Price Target

12 USD

Spread / Lowest Target

+8.79%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Roivant Sciences Ltd.

Deutsche Bank Securities
Goldman Sachs
HC Wainwright
Wolfe Research
Truist Securities
BofA Securities
JPMorgan Chase
Citigroup
SVB Securities LLC
Cantor Fitzgerald
SVB Leerink
Jefferies & Co.
Cowen

Ratings for Roivant Sciences Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar